Smartlens, Inc. has secured $5,200,000 in a recent funding round from investors. The company specializes in transforming eye care through groundbreaking monitoring and treatment technologies, particularly for managing glaucoma and other anterior segment eye diseases. This investment underscores investor confidence in Smartlens's mission to convert traditional eye care into personalized, proactive disease management, addressing unmet needs in the field since the 1950s with solutions designed for millions of patients worldwide.
Smartlens's comprehensive platform combines a breakthrough, electronics-free contact lens for remote intraocular pressure (IOP) monitoringa primary risk factor for glaucoma, the leading cause of irreversible blindnesswith a smart drug delivery platform that optimizes treatment timing and patient compliance. The platform also includes an advanced AI-powered imaging system serving as a smart slit lamp for remote disease management. The company's solutions, protected by patents in over 40 countries and backed by prominent VC firms and Stanford University, have demonstrated strong clinical results, with commercialization planned for 2026.
Smartlens plans to strategically deploy the newly raised capital to accelerate its research and development initiatives, scale operational capabilities, and prepare for the upcoming commercialization of its innovative technologies. The company has previously been recognized by Nature Medicine, Fortune, and BBC, and received the "Outstanding Innovation in Medical Technology and Life Sciences" award in 2021. This funding is crucial for advancing Smartlens's commitment to building a world where eye diseases no longer compromise quality of life, ensuring better outcomes for patients globally as it moves closer to its commercial launch.
